{
    "nct_id": "NCT05224141",
    "official_title": "A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer",
    "inclusion_criteria": "* Has histologically or cytologically confirmed diagnosis of ES-SCLC in need of first-line therapy\n* Has ES-SCLC defined as Stage IV (T any, N any, M1a/b/c) by the American Joint Committee on Cancer, Eighth Edition or T3-T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan\n* Males agree to use contraception, refrain from donating sperm, and abstain from heterosexual intercourse\n* Females are not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) or is a WOCBP who uses a highly effective contraceptive method, or is abstinent from heterosexual intercourse\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1\n* Has a predicted life expectancy of >3 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Is considered a poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease\n* Has received prior treatment for Small Cell Lung Cancer (SCLC)\n* Is expected to require any other form of antineoplastic therapy for SCLC while on study\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has a history of severe hypersensitivity reaction (â‰¥Grade 3) to any study intervention and/or any of its excipients\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease\n* Has a known history of, or active, neurologic paraneoplastic syndrome\n* Has an active infection requiring systemic therapy\n* Has a known history of human immunodeficiency virus (HIV) infection\n* Has a known history of Hepatitis B or known active Hepatitis C virus infection\n* Has had an allogenic tissue/solid organ transplant\n* Has had major surgery within prior 3 weeks or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study intervention\n* Has symptomatic ascites or pleural effusion",
    "miscellaneous_criteria": ""
}